scholarly journals Correlation of Lipid Peroxidation and Glutathione Levels with severity of Systemic Lupus Erythematosus: a Pilot study from Single Center

2008 ◽  
Vol 11 (3) ◽  
pp. 30 ◽  
Author(s):  
Karunrat Tewthanom
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Oxidative Status ◽  
Glutathione Level ◽  
Limited Data ◽  
Systemic Lupus ◽  
Plasma Glutathione ◽  
Chronic Autoimmune Disease ◽  
Possible Cause ◽  
Plasma Malondialdehyde

Abstract Systemic Lupus Erythematosus (SLE) is a multifactoral chronic autoimmune disease with unidentified etiology. Imbalance of oxidative status is one possible cause of active disease. Plasma malondialdehyde (MDA) and plasma glutathione (GSH) level have been used as a determinate of oxidative status. Limited data has examined these 2 parameters by severity of SLE. Therefore, the purpose of this study was to determine if an association between plasma MDA and plasma GSH level with the severity of SLE . Twenty healthy volunteers (3 Men, 17 women) and 44 SLE patients (2 Men and 42 Women) participated in this study. SLE participants were classified by the severity of disease (mild, moderate or severe). The plasma MDA and plasma Glutathione level were measured. The correlation of plasma MDA and plasma Glutathione levels with the severity of SLE disease were determined. No correlation of plasma MDA level among the 4 groups with different severity of SLE (Control, mild, moderate, and severe of SLE patients) was observed at p

scholarly journals Dendritic cells’ characteristics in patients with treated systemic lupus erythematosus

2020 ◽  
Author(s):  
Anna Wardowska ◽  
Żaneta Smoleńska ◽  
Katarzyna A. Lisowska ◽  
Zbigniew Zdrojewski ◽  
Michał Pikuła
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Dendritic Cells ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Complement Components ◽  
Expression Of Genes ◽  
Luminex Technology ◽  
Transcriptional Changes ◽  
Chronic Autoimmune Disease

The systemic lupus erythematosus (SLE) is a chronic autoimmune disease related to a loss of immune tolerance against autoantigens that leads to tissue inflammation and organ dysfunction. Constant stimulation of dendritic cells (DC) with autoantigens is hypothesized to increase the B cells’ activity which are involved in production of autoantibodies that play an essential role in the SLE development. We focused our study on detecting alterations in DCs at the cellular and molecular levels in patients with treated SLE, depending on the disease activity and treatment. In order to phenotype subpopulations of DCs, multicolor flow cytometry was used. Transcriptional changes were identified with quantitative PCR, while soluble cytokine receptors were assessed with the Luminex technology. We show that SLE patients display a higher percentage of activated myeloid DCs (mDCs) when compared to healthy people. Both, the mDCs and plasmacytoid DCs (pDCs) of SLE patients were characterized by changes in expression of genes associated with their maturation, functioning and signalling, which was especially reflected by low expression of regulatory factor ID2 and increased expression of IRF5. pDCs of SLE patients also showed increased expression of IRF1. There were also significant changes in the expression of APRIL, MBD2, and E2-2 in mDCs that significantly correlated with some serum components, i.e. anti-dsDNA antibodies or complement components. However, we did not find any significant differences depending on the disease activity. While the majority of available studies focuses mainly on the role of pDCs in the disease development, our results show significant disturbances in the functioning of mDCs in SLE patients, thus confirming mDCs’ importance in SLE pathogenesis.

scholarly journals Recent advances in the management of systemic lupus erythematosus

F1000Research ◽  
2018 ◽  
Vol 7 ◽  
pp. 970 ◽  
Author(s):  
Savino Sciascia ◽  
Massimo Radin ◽  
Dario Roccatello ◽  
Giovanni Sanna ◽  
Maria Laura Bertolaccini
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Side Effects ◽  
Autoimmune Disease ◽  
Lupus Erythematosus ◽  
Clinical Manifestations ◽  
Therapeutic Strategies ◽  
Systemic Lupus ◽  
Systemic Involvement ◽  
Phase Ii And Iii ◽  
Chronic Autoimmune Disease

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease presenting highly heterogeneous clinical manifestations and multi-systemic involvement. Patients are susceptible to relapse­ and remission, thus making management challenging. Moreover, a considerable number of side effects may occur with conventional therapies; therefore, there is clearly a need for new therapeutic strategies. Since the pathogenesis of SLE is highly complex, it is far from being fully understood. However, greater understanding of the pathways and of the cellular and molecular mediators involved in SLE is being achieved. Emerging evidence has allowed the development of new biological therapeutic options targeting crucial molecular mediators involved in the pathogenesis of SLE. This literature review analyzes the availability of biological and target-directed treatments, phase II and III trials, and new therapies that are being developed for the treatment of SLE.

scholarly journals AUTOIMMUNE MYELOFIBROSIS ASSOCIATED WITH SYSTEMIC LUPUS ERYTHEMATOSUS: EXCEPTIONALLY RARE OR UNDERRECOGNIZED?

2021 ◽  
Vol 2 (2) ◽  
pp. 96-100
Author(s):  
Döndü Üsküdar Cansu ◽  
Cengiz Korkmaz
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Bone Marrow ◽  
Lupus Erythematosus ◽  
Case Reports ◽  
Classification Criteria ◽  
Systemic Lupus ◽  
Organ Systems ◽  
Hematological Abnormalities ◽  
Chronic Autoimmune Disease ◽  
Rare Symptom

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease which may involve several organs or organ systems. SLE may also have hematological as well as joint, kidney, and central nervous system involvements. Hematological abnormalities such as anemia, leukopenia, thrombocytopenia, and autoimmune hemolytic anemia are the best-known and most common hematological findings detected in SLE patients which are included in the classification criteria for SLE.  Autoimmune myelofibrosis (AIMF) refers to bone marrow (BM) fibrosis (myelofibrosis) that develops in an autoimmune setting. Myelofibrosis is not among the SLE classification criteria and it is also not well-known. Current reports in the literature on SLE-associated AIMF are mostly restricted to case reports or reviews of such case reports. The occurrence of BM fibrosis in SLE patients has been explored merely in few studies which concluded that myelofibrosis is a rare symptom of SLE. Herein, we propose the hypothesis that SLE-associated AIMF is not rare and, on the contrary, it can indeed be more frequent than what is known or expected.

scholarly journals Vesiculobollous disease with Cutaneous Systemic Lupus Erythematosus Treated by Rituxima; a case report

2021 ◽  
Author(s):  
Wigdan Mohammed Niamat Alla ◽  
Burhan Mohamed Ali Ahmed ◽  
Mohammed Elmujtba Adam Essa ◽  
Atif Elhadi Abdalla Babker ◽  
Elnour Mohammed Elagib
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Case Report ◽  
Autoimmune Disease ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Chronic Autoimmune Disease

SLE is a chronic autoimmune disease characterized by multisystem inflammation, Vesiculobullous (VB) are different groups of oral disorders characterized by the formation of bullae. The aim of this report is to describe a case of a vesiculobullous disease in SLE.

scholarly journals Childhood onset SLE- case report

2021 ◽  
Vol 11 (3) ◽  
pp. 32-33
Author(s):  
Awal Alhusain ◽  
Hasan Alhashim ◽  
Wafa Almuraidif ◽  
Mariam Alghazal ◽  
Awal Alhusain ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Native Americans ◽  
Lupus Erythematosus ◽  
Age Of Onset ◽  
Significant Morbidity ◽  
Childhood Onset ◽  
Systemic Lupus ◽  
The Times ◽  
Chronic Autoimmune Disease ◽  
Children Under 5

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect any organ and may result in significant morbidity and mortality. Childhood-onset c-SLE is a rare disease with an incidence of 0.3-0.9/100,000 children-years and a prevalence of 3.3-8.8/100,000 children.1 Asians, African American, Hispanic and Native Americans have higher frequency of the disease.2,3 Similar to adult SLE, c-SLE affects mainly females with around 80% of the affected children. According to the literature, the median age of onset is 11-12 years and it is rare in children under 5 years of age. The manifestations of c-SLE are variable and most of the times are atypical compared to adult SLE which make the diagnosis of cSLE a challenge to the treating physician.4 This report shows a series of presentation in pediatric patient who finally was diagnosed with SLE.

Association between systemic lupus erythematosus and thyroid dysfunction: a meta-analysis

Lupus ◽  
2018 ◽  
Vol 27 (13) ◽  
pp. 2120-2128 ◽  
Author(s):  
W Luo ◽  
P Mao ◽  
L Zhang ◽  
Z Yang
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Subclinical Hypothyroidism ◽  
Thyroid Dysfunction ◽  
Meta Analysis ◽  
Healthy Controls ◽  
Subclinical Hyperthyroidism ◽  
Systemic Lupus ◽  
Increased Risk ◽  
Chronic Autoimmune Disease

Introduction Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, the pathogenesis of which remains elusive. The deficiency or excess of thyroid hormone is defined as thyroid dysfunction, including (subclinical) hypothyroidism and (subclinical) hyperthyroidism. Autoimmune factors are likely to be relevant to the development of SLE and thyroid dysfunction. Recently, many studies have indicated that the prevalence of thyroid dysfunction is higher in SLE patients than in the general population. The objective of our study was to perform a systematic review and meta-analysis to find out the relationship between SLE and thyroid dysfunction. Methods Literature databases were searched, including PubMed, Embase, Web of science, Cochrane, CNKI, CHINESE WANFANG, China Science and Technology Database (VIP). Studies comparing presence of thyroid dysfunction in SLE patients to healthy controls were extracted. All the statistical analyses were performed with STATA 12.0 software. Results Ten studies with 10,500 SLE patients and 44,170 healthy controls were included in this study. The meta-analysis results showed that the prevalence of (subclinical) hypothyroidism in SLE patients was higher than in the healthy controls (hypothyroidism: OR = 2.93, 95% CI = 1.81–4.75; subclinical hypothyroidism: OR = 5.67, 95% CI = 3.50–9.18). No statistical difference of (subclinical) hyperthyroidism was found between SLE patients and controls. Conclusion Our meta-analysis suggests that SLE is significantly associated with increased risk of (subclinical) hypothyroidism, but it has little influence on (subclinical) hyperthyroidism.

scholarly journals Correlation between physical markers and psychiatric health in a Portuguese systemic lupus erythematosus cohort: The role of suffering in chronic autoimmune disease

PLoS ONE ◽  
2018 ◽  
Vol 13 (4) ◽  
pp. e0195579 ◽  
Author(s):  
Margarida Figueiredo-Braga ◽  
Caleb Cornaby ◽  
Miguel Bernardes ◽  
Marta Figueiredo ◽  
Cristina Dos Santos Mesquita ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Autoimmune Disease ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Chronic Autoimmune Disease

scholarly journals Inherited thrombophilias could influence the reproductive outcome in women with systemic lupus erythematosus

2017 ◽  
Vol 20 (1) ◽  
pp. 21-26 ◽  
Author(s):  
R Robeva ◽  
D Tanev ◽  
S Andonova ◽  
M Nikolova ◽  
A Tomova ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Clinical Importance ◽  
Rflp Analysis ◽  
Reproductive History ◽  
Systemic Lupus ◽  
Pcr Rflp ◽  
History Of ◽  
Caucasian Women ◽  
Chronic Autoimmune Disease

AbstractSystemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with different reproductive complications in the affected women. Inherited thrombophilias are genetic factors increasing the risk for thromboembolism and recurrent pregnancy loss, but their influence on other reproductive disturbances in SLE patients has not been completely clarified. Two hundred and twenty-three Caucasian women (112 with SLE and 111 controls) were included in the study. Complete reproductive history of all SLE patients was carefully obtained. Genotyping for the FVLeiden, FIIG20210A, and MTHFRC677Tpolymorphisms was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. No significant differences in the prevalence of the FVLeiden, FIIG20210A, and MTHFRC677Tpolymorphisms between patients and controls were established. Patients with FVLeidenhad fewer pregnancies (0.57 ± 0.98vs. 2.18 ± 1.58;p= 0.007) than the others, while no significant differences in the reproductive history of FIIG20210Acarriers and non-carriers were observed (p>0.05). In the SLE group, 41.67% of women with the MTHFRC677TTT genotype had at least one miscarriage in comparison to only 14.00% of the other female patients (p= 0.030). While the prevalence of the investigated thrombophilias was similar in patients with SLE and healthy women, a substantial influence of the inherited prothrombotic factors on the reproductive history of patients was revealed. The investigations of the FVLeidenand MTHFRC677Tpolymorphisms in SLE patients could help to identify women at highest risk for reproductive failure and thus, further studies in other ethnic groups would be of strong clinical importance.

Sign in / Sign up

Export Citation Format

Share Document